Anticancer drug targets: approaching angiogenesis.
作者信息
Keshet E, Ben-Sasson S A
机构信息
Department of Molecular Biology, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel.
出版信息
J Clin Invest. 1999 Dec;104(11):1497-501. doi: 10.1172/JCI8849.
Abstract
摘要
相似文献
1
Anticancer drug targets: approaching angiogenesis.
J Clin Invest. 1999 Dec;104(11):1497-501. doi: 10.1172/JCI8849.
2
Angiogenesis and antiangiogenic therapy.
Curr Probl Cancer. 2002 Jan-Feb;26(1):1-60.
3
[Antiangiogenic therapy].
Gan To Kagaku Ryoho. 1998 Nov;25(13):2003-9.
4
[Research on the endothelium and new therapeutic strategies in tumors and cardiovascular diseases].
Recenti Prog Med. 1999 Feb;90(2):64-8.
5
Evidence of efficacy: researchers investigating markers for angiogenesis inhibitors.
J Natl Cancer Inst. 2003 Oct 1;95(19):1425-7. doi: 10.1093/jnci/95.19.1425.
6
Endothelial survival factors as targets for antineoplastic therapy.
Cancer J. 2001 Nov-Dec;7 Suppl 3:S109-19.
7
Advances in the use of angiogenesis inhibitors in cancer.
Cancer J. 2001 Nov-Dec;7 Suppl 3:S107-8.
8
Therapeutic angiogenesis inhibitors in the treatment of cancer.
Adv Intern Med. 2001;47:159-90.
9
Science, medicine, and the future. Antivascular therapy: a new approach to cancer treatment.
BMJ. 1999 Mar 27;318(7187):853-6. doi: 10.1136/bmj.318.7187.853.
10
[Therapeutic prospects of angiogenesis inhibitors in cancerology].
Rev Mal Respir. 1999 Nov;16(5):854-5.
引用本文的文献
1
Ocular pharmacological and biochemical profiles of 6-thioguanine: a drug repurposing study.
Front Pharmacol. 2024 Mar 25;15:1375805. doi: 10.3389/fphar.2024.1375805. eCollection 2024.
2
Nifuroxazide Mitigates Angiogenesis in Ehlrich's Solid Carcinoma: Molecular Docking, Bioinformatic and Experimental Studies on Inhibition of Il-6/Jak2/Stat3 Signaling.
Molecules. 2021 Nov 13;26(22):6858. doi: 10.3390/molecules26226858.
3
A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors.
Invest New Drugs. 2019 Aug;37(4):658-665. doi: 10.1007/s10637-018-0690-x. Epub 2018 Oct 31.
4
Zerumbone Suppresses Angiogenesis in HepG2 Cells through Inhibition of Matrix Metalloproteinase-9, Vascular Endothelial Growth Factor, and Vascular Endothelial Growth Factor Receptor Expressions.
Pharmacogn Mag. 2018 Jan;13(Suppl 4):S731-S736. doi: 10.4103/pm.pm_18_17. Epub 2018 Jan 31.
5
Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer.
Cancers (Basel). 2018 Jan 27;10(2):34. doi: 10.3390/cancers10020034.
6
Wnt Signaling in Renal Cell Carcinoma.
Cancers (Basel). 2016 Jun 17;8(6):57. doi: 10.3390/cancers8060057.
7
Antiangiogenesis, loss of cell adhesion and apoptosis are involved in the antitumoral activity of Proteases from V. cundinamarcensis (C. candamarcensis) in murine melanoma B16F1.
Int J Mol Sci. 2015 Mar 27;16(4):7027-44. doi: 10.3390/ijms16047027.
8
Anti-proliferative and angio-suppressive effect of Stoechospermum marginatum (C. Agardh) Kutzing extract using various experimental models.
Nutr Res Pract. 2014 Aug;8(4):377-85. doi: 10.4162/nrp.2014.8.4.377. Epub 2014 May 15.
9
Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review.
Transl Oncol. 2012 Jun;5(3):133-40. doi: 10.1593/tlo.12118. Epub 2012 Jun 1.
10
Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity.
Sensors (Basel). 2009;9(8):6471-503. doi: 10.3390/s90806471. Epub 2009 Aug 20.
本文引用的文献
1
Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein.
J Clin Invest. 1999 Dec;104(11):1583-91. doi: 10.1172/JCI8161.
2
Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry.
Am J Pathol. 1999 Sep;155(3):739-52. doi: 10.1016/S0002-9440(10)65173-5.
3
Anti-cancer activity of targeted pro-apoptotic peptides.
Nat Med. 1999 Sep;5(9):1032-8. doi: 10.1038/12469.
4
Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis.
Nat Med. 1999 Jul;5(7):793-802. doi: 10.1038/10518.
5
Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.
Science. 1999 Jun 18;284(5422):1994-8. doi: 10.1126/science.284.5422.1994.
6
Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development.
Genes Dev. 1999 May 1;13(9):1055-66. doi: 10.1101/gad.13.9.1055.
7
Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention.
J Clin Invest. 1999 May;103(9):1237-41. doi: 10.1172/JCI6870.
8
The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.
J Clin Invest. 1999 May;103(9):1227-30. doi: 10.1172/JCI6869.
9
Effects of angiogenesis inhibitors on multistage carcinogenesis in mice.
Science. 1999 Apr 30;284(5415):808-12. doi: 10.1126/science.284.5415.808.
10
Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.
J Clin Invest. 1999 Jan;103(2):159-65. doi: 10.1172/JCI5028.
Zotero 插件